Visual processing suppression

Visual processing suppression is a reduction in the brain's ability to interpret incoming visual information, in which the environment loses legibility despite open eyes.

As a drug effect it is acute and high-dose-dependent, easing as the substance wears off, which distinguishes it from clinical visual impairment. It ranges from mild blunting of visual clarity and difficulty resolving detail to near-total loss of meaningful perception, in which the visual field collapses into an undifferentiated blur or darkness.

It is uncommon relative to other perceptual effects and appears almost exclusively at high doses. It is most commonly induced under dissociatives such as ketamine and dextromethorphan, and at high doses under psychedelics such as 25B-NBOH, 25C-NBOH, and 25I-NBOH. It also appears under depressants including gabapentin, methaqualone, and pregabalin, and at high doses of cannabinoids such as cannabis.

Visual processing suppression is felt as a progressive hollowing of sight: the eyes register light but the brain fails to render it into a coherent scene. Objects lose their shapes, faces become unreadable, and text stops resolving into legible symbols. Depth cues flatten.

It commonly comes with a matching detachment from the body and a quieting of inner speech, as if the channels that normally interpret the world have gone offline together. Focusing harder yields nothing — attention finds no foothold in the visual field. At high doses, particularly under dissociatives, the field collapses entirely into undifferentiated darkness or formless haze.

Visual processing suppression arises through different pathways depending on the drug class:

• Dissociatives — block NMDA receptors, disrupting the thalamocortical relay that carries visual signals to the cortex; at high doses this produces near-complete interruption of visual scene construction.
• Psychedelics — at high doses, intense 5-HT2A engagement in visual cortex overwhelms rather than amplifies processing, collapsing organized perception into noise.
• Depressants — broad CNS depression reduces activity across visual processing pathways alongside motor and cognitive suppression.
• Cannabinoids — CB1 activity disrupts attentional gating of visual input at high doses.

How much each pathway contributes in a given case is not fully understood.

Who experiences it, and how strongly, varies widely. It is strongly dose-gated — at low to moderate doses the same substances typically produce visual enhancement or distortion rather than suppression. Combining a dissociative with a depressant lowers the effective threshold.

Individual neurological sensitivity plays a larger role than set and setting, which matters less here than in emotionally toned effects. Expectation has minimal pull in a primarily pharmacological suppression, though prior high-dose experience gives users a frame of reference that reduces alarm without changing the effect's depth.